ReviewBone2011
Tumor-host cell interactions in the bone disease of myeloma.
Review in Bone, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 54 citations in OpenAlex.
- An overview of pim kinase as a target in multiple myeloma.Cancer medicine · 2023Review
- Generation of Induced Pluripotent Stem Cells from Patients with Multiple MyelomaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2021Article
- Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway.Cancer epidemiology · 2021Article
- Management of Myeloma Bone Lesions.International journal of molecular sciences · 2021Review
- Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment.Scientific reports · 2019Article
- Current Perspectives in Cancer Immunotherapy.Cancers · 2019Review
- Tissue engineered models of healthy and malignant human bone marrow.Advanced drug delivery reviews · 2019Review
- Improving knowledge on the activation of bone marrow fibroblasts in MGUS and MM disease through the automatic extraction of genes via a nonnegative matrix factorization approach on gene expression profiles.Journal of translational medicine · 2018Article
- Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential.Journal of hematology & oncology · 2018Review
- Multiple Myeloma Exemplifies a Model of Cancer Based on Tissue Disruption as the Initiator Event.Frontiers in oncology · 2018Article
- Impact of connexin 43 coupling on survival and migration of multiple myeloma cells.Archives of medical science : AMS · 2017Article
- Cx43 expressed on bone marrow stromal cells plays an essential role in multiple myeloma cell survival and drug resistance.Archives of medical science : AMS · 2017Article
- A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease.International journal for numerical methods in biomedical engineering · 2016Article
- Multiple myeloma in the marrow: pathogenesis and treatments.Annals of the New York Academy of Sciences · 2016Review
- Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.The Journal of clinical investigation · 2015Article
- Review
- The Forkhead Transcription Factor FOXP2 Is Required for Regulation of p21WAF1/CIP1 in 143B Osteosarcoma Cell Growth Arrest.PloS one · 2015Article
- unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2014Review
- Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease.International journal for numerical methods in biomedical engineering · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Multiple myeloma is a hematological malignancy that is associated with the development of a destructive osteolytic bone disease, which is a major cause of morbidity for patients with myeloma. Interactions between myeloma cells and cells of the bone marrow microenvironment promote both tumor growth and survival and bone destruction, and the osteolytic bone disease is now recognized as a contributing component to tumor progression. Since myeloma bone disease is associated with both an increase in osteoclastic bone resorption and a suppression of osteoblastic bone formation, research to date has largely focused upon the role of the osteoclast and osteoblast. However, it is now clear that other cell types within the bone marrow, including cells of the immune system, mesenchymal stem cells and bone marrow stromal cells, can contribute to the development of myeloma bone disease. This review discusses the cellular mechanisms and potential therapeutic targets that have been implicated in myeloma bone disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.